appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Biocon Ltd
BIOCON
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Hester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Transgene Biotek Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Trade setup for Wednesday: 15 things to know before opening bell
2 days ago•Moneycontrol
Biocon Onboards Local Partner For Diabetes Drug In Brazil
1 week ago•Bloomberg Quint
Biocon Q4 PAT may dip 192.8% YoY to Rs 67.1 cr: ICICI Securities
1 week ago•Moneycontrol
Recent EventsAll events
Shareholders meeting
Biocon Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download
Biocon Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download
Press Release
Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.". | Download
Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.". | Download
Cash Dividend
Final • Div/Share: ₹ 1.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant